Conference Coverage

Retatrutide at ADA 2026: TRIUMPH-1 and TRANSCEND-T2D-1 Deliver — and Get Published in The Lancet

At the ADA 2026 Scientific Sessions (June 6), retatrutide's pivotal TRIUMPH-1 obesity and TRANSCEND-T2D-1 diabetes results were presented in full — with TRANSCEND-T2D-1 published simultaneously in The Lancet. Beyond weight loss, nested baskets showed 73.1% knee-pain and 60.6% sleep-apnea reductions.